Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial

Sung Won Choi(University of Michigan), Pavan Reddy(Wichita State University), Attaphol Pawarode(University of Michigan), James L.M. Ferrara(Tisch Hospital), Jan H. Beumer(Johns Hopkins University), Charles A. Dinarello(University of Colorado Anschutz Medical Campus), Michael H. Lehmann(University of Pavia), Isao Tawara(Mie University), John E. Levine(Icahn School of Medicine at Mount Sinai), Sophie Paczesny(MUSC Hollings Cancer Center), John F. DiPersio(Washington University in St. Louis), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Steven A. Goldstein(University of California, Irvine), Carrie L. Kitko(Vanderbilt University Medical Center), Gregory A. Yanik(University of Michigan), Keith Stockerl‐Goldstein(City Of Hope National Medical Center), Guoqing Hou(University of Michigan), Thomas Braun(University of Michigan), Lawrence Chang(University of Michigan), Markus Y. Mapara(Sheba Medical Center), Yaping Sun(Jinan Central Hospital), John Magenau(University of Michigan)
The Lancet Oncology
November 29, 2013
Cited by 131


Related Papers